Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® []Trial in Breast Cancer Associated Lymphedema
Key Highlights: · Safety and tolerability maintained through to 24 months · Clinically meaningful improvements after 12 months, maintained out to 24 months · Top-line data for follow on Phase II study expected in Q1 2021 after 12 months blinded follow-up Herantis Pharma Plc Company release, 17 November 2020 at 9:00 a.m. Eastern European Time Herantis Pharma Plc (“Herantis”), an innovative drug development company pioneering new disease modifying and regenerative biologic and gene therapies, today announced its novel gene therapy candidate Lymfactin®, a Vascular